Alan H. Auerbach Sells 18,885 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach sold 18,885 shares of Puma Biotechnology stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total value of $61,753.95. Following the completion of the sale, the chief executive officer now owns 7,085,435 shares in the company, valued at $23,169,372.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Puma Biotechnology Stock Performance

Shares of PBYI stock opened at $3.02 on Thursday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.46. The stock has a market cap of $145.68 million, a PE ratio of 9.15 and a beta of 1.09. Puma Biotechnology, Inc. has a 1 year low of $2.13 and a 1 year high of $7.73. The stock has a fifty day moving average price of $3.95 and a 200 day moving average price of $4.79.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.12. The business had revenue of $43.80 million during the quarter, compared to the consensus estimate of $41.53 million. Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. Sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.22 earnings per share for the current fiscal year.

Institutional Trading of Puma Biotechnology

Large investors have recently modified their holdings of the business. Acadian Asset Management LLC lifted its stake in Puma Biotechnology by 2.0% in the 1st quarter. Acadian Asset Management LLC now owns 1,956,513 shares of the biopharmaceutical company’s stock valued at $10,366,000 after buying an additional 39,239 shares in the last quarter. Great Point Partners LLC purchased a new stake in shares of Puma Biotechnology in the fourth quarter valued at $4,734,000. GSA Capital Partners LLP boosted its stake in shares of Puma Biotechnology by 143.8% during the third quarter. GSA Capital Partners LLP now owns 279,629 shares of the biopharmaceutical company’s stock valued at $735,000 after acquiring an additional 164,931 shares during the last quarter. Citigroup Inc. purchased a new stake in Puma Biotechnology during the 3rd quarter worth about $262,000. Finally, Assenagon Asset Management S.A. increased its position in Puma Biotechnology by 23.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 85,039 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 15,897 shares in the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. StockNews.com raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 12th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Monday, June 3rd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.